

Institutional Biosafety Committee
Ad Hoc Meeting
February 28, 2005
Dean's Large Conference Room, Icahn Building, First Floor

Present: J. Wetmur, P. Hauck, D. Calfee, S. Strauss.

Present via conference telephone: L. Egan, F. Erlitz; R. Wieder

Dr. Wetmur asked Mr. Hauck to summarize the case for the Committee.

Mr. Hauck explained that Dr. Jeffrey Olin is participating in a multicenter study of a Proprietary-product for treating claudication with a gene vector system, which promotes revascularization in hypoxic tissue. The vector promotes blood vessel growth only at the local site, not globally. These viruses are well characterized and have been used for several years.

Dr. Wetmur noted that the vector clears from the site in approximately 60 days.

He also noted for the record that the approval of the IBC comes following NIH approval, a reversal of the usual sequence.

Dr. Wetmur recommends handling this virus at BSL 2, even though it could be managed at a lower level. The only danger of exposure for workers will be from needle sticks.

Dr. Wetmur called for objections; there were none.

Changes to the letter to Dr. Olin advised by Dr. Calfee were approved:

Recommendation: Drop the phrase " Standard Precautions for BloodBorne Pathogens" and leave Standard Precautions, since it is redundant, and is understood to refer to BloodBorne Pathogens

Recommendation 3. "disposed of in the appropriate receptacles" will read "in the appropriate regulated medical waste containers."

Recommendation that the protocol be reviewed by MSMC Infection Control will be deleted since Dr. David Calfee of the Biosafety Committee is also the Mount Sinai Infection Control officer and has reviewed the protocol.

Upon motion duly made and seconded, a BSL 2 safety level for this project was unanimously approved.